Skip to main content

Therapiestrategien bei systemischen Vaskulitiden

Treatment strategies in systemic vasculitis

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Zusammenfassung

Die Therapie der Vaskulitiden umfasst heutzutage die gesamte Breite der konventionellen immunsuppressiven Medikamente sowie einzelne Biologika (insbesondere Rituximab). Im Einzelfall wird die medikamentöse Therapie bei Patienten mit Befall von mittleren und insbesondere großen Gefäßen durch angiologische Interventionen und gefäßchirurgische Operationen ergänzt, um Komplikationen wie Aneurysmen oder ischämische Verschlüsse von Gefäßen zu beheben. Dieser Artikel gibt einen Überblick über die Grundzüge v. a. der medikamentösen Therapie der Vaskulitiden, geht aber auch auf häufig durchgeführte interventionelle/operative Verfahren ein.

Abstract

The treatment of vasculitides nowadays comprises the complete spectrum of immunosuppressive agents including some biologicals (particularly rituximab). In addition to pharmacotherapy, angiological interventional and vascular surgical procedures are performed in patients with medium or large vessel vasculitis in order to address complications, such as aneurysms or ameliorate ischemic vessel occlusion. This article gives an overview of the basic principles of medicinal treatment strategies in systemic vasculitis and, in addition, discusses frequently performed interventional and surgical procedures.

This is a preview of subscription content, access via your institution.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Buttgereit F, Matteson EL, Dejaco C, Dasgupta B (2018) Prevention of glucocorticoid morbidity in giant cell arteritis. Rheumatology (Oxf) 57:ii11–ii21

    Article  Google Scholar 

  2. Ertz-Archambault N, Kosiorek H, Taylor GE et al (2017) Association of therapy for autoimmune disease with Myelodysplastic syndromes and acute Myeloid leukemia. Jama Oncol 3:936–943

    PubMed Central  Article  PubMed  Google Scholar 

  3. Monach PA, Arnold LM, Merkel PA (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 62:9–21

    CAS  Article  PubMed  Google Scholar 

  4. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW (2017) Long-term systemic Corticosteroid exposure: a systematic literature review. Clin Ther 39:2216–2229

    CAS  Article  PubMed  Google Scholar 

  5. Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323

    CAS  Article  PubMed  Google Scholar 

  6. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B (2016) Polymyalgia Rheumatica and giant cell arteritis: a systematic review. JAMA 315:2442–2458

    CAS  Article  PubMed  Google Scholar 

  7. Hayreh SS, Biousse V (2012) Treatment of acute visual loss in giant cell arteritis: Should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol 32:278–287

    Article  PubMed  Google Scholar 

  8. Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of Tocilizumab in giant-cell arteritis. N Engl J Med 377:317–328

    CAS  Article  PubMed  Google Scholar 

  9. Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789–2797

    CAS  Article  PubMed  Google Scholar 

  10. Villiger PM, Adler S, Kuchen S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921–1927

    CAS  Article  PubMed  Google Scholar 

  11. De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45:136–138

    PubMed Central  Article  PubMed  Google Scholar 

  12. Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837–845

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  13. Conway R, O’Neill L, Gallagher P et al (2018) Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2018.04.004

    Article  PubMed  Google Scholar 

  14. de Boysson H, Boutemy J, Creveuil C et al (2013) Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 43:105–112

    Article  CAS  PubMed  Google Scholar 

  15. Evans JM, Bowles CA, Bjornsson J, Mullany CJ, Hunder GG (1994) Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 37:1539–1547

    CAS  Article  PubMed  Google Scholar 

  16. Gagne-Loranger M, Dumont E, Voisine P et al (2016) Giant cell aortitis: clinical presentation and outcomes in 40 patients consecutively operated on. Eur J Cardiothorac Surg 50:555–559

    Article  PubMed  Google Scholar 

  17. Salvarani C, Bella CD, Cimino L et al (2009) Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxf) 48:250–253

    CAS  Article  Google Scholar 

  18. Narvaez J, Bernad B, Gomez-Vaquero C et al (2008) Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 26:S57–S62

    CAS  PubMed  Google Scholar 

  19. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50:1332–1337

    CAS  Article  PubMed  Google Scholar 

  20. Lee MS, Smith SD, Galor A, Hoffman GS (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54:3306–3309

    Article  PubMed  Google Scholar 

  21. Goel R, Danda D, Mathew J, Edwin N (2010) Mycophenolate mofetil in Takayasu’s arteritis. Clin Rheumatol 29:329–332

    Article  PubMed  Google Scholar 

  22. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582

    CAS  Article  PubMed  Google Scholar 

  23. de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI (2012) Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41:227–230

    Article  CAS  PubMed  Google Scholar 

  24. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304

    CAS  Article  PubMed  Google Scholar 

  25. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567–1569

    CAS  Article  PubMed  Google Scholar 

  26. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798

    CAS  PubMed  Google Scholar 

  27. Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu’s arteritis and its therapy. Ann Intern Med 103:121–126

    CAS  Article  PubMed  Google Scholar 

  28. Nakaoka Y, Isobe M, Takei S et al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348–354

    CAS  Article  PubMed  Google Scholar 

  29. Zheng T, Zhu S, Ou JF et al (2018) Treatment with corticosteroid and/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu’s arteritis. J Invest Surg. https://doi.org/10.1080/08941939.2017.1408718

    Article  PubMed  Google Scholar 

  30. Perera AH, Youngstein T, Gibbs RG, Jackson JE, Wolfe JH, Mason JC (2014) Optimizing the outcome of vascular intervention for Takayasu arteritis. Br J Surg 101:43–50

    CAS  Article  PubMed  Google Scholar 

  31. Gulcu A, Gezer NS, Akar S, Akkoc N, Onen F, Goktay AY (2017) Long-term follow-up of endovascular repair in the management of arterial stenosis caused by Takayasu’s arteritis. Ann Vasc Surg 42:93–100

    Article  PubMed  Google Scholar 

  32. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH (2006) Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu’s arteritis. Rheumatology (Oxf) 45:600–605

    CAS  Article  Google Scholar 

  33. Liang P, Tan-Ong M, Hoffman GS (2004) Takayasu’s arteritis: vascular interventions and outcomes. J Rheumatol 31:102–106

    PubMed  Google Scholar 

  34. Fields CE, Bower TC, Cooper LT et al (2006) Takayasu’s arteritis: operative results and influence of disease activity. J Vasc Surg 43:64–71

    Article  PubMed  Google Scholar 

  35. Jung JH, Lee YH, Song GG, Jeong HS, Kim JH, Choi SJ (2018) Endovascular versus open surgical intervention in patients with Takayasu’s arteritis: a meta-analysis. Eur J Vasc Endovasc Surg 55:888–899

    Article  PubMed  Google Scholar 

  36. Jeong HS, Jung JH, Song GG, Choi SJ, Hong SJ (2017) Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: a meta-analysis. Medicine (Baltimore) 96:e7558

    PubMed Central  Article  PubMed  Google Scholar 

  37. Matsuura K, Ogino H, Kobayashi J et al (2005) Surgical treatment of aortic regurgitation due to Takayasu arteritis: long-term morbidity and mortality. Circulation 112:3707–3712

    Article  PubMed  Google Scholar 

  38. Vaglio A, Palmisano A, Alberici F et al (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 378:338–346

    CAS  Article  PubMed  Google Scholar 

  39. Vaglio A, Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet 367:241–251

    Article  PubMed  Google Scholar 

  40. van der Bilt FE, Hendriksz TR, van der Meijden WA, Brilman LG, van Bommel EF (2016) Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J 9:184–191

    PubMed Central  Article  PubMed  Google Scholar 

  41. van Bommel EF, Pelkmans LG, van Damme H, Hendriksz TR (2013) Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 24:444–450

    Article  CAS  PubMed  Google Scholar 

  42. Adler S, Lodermeyer S, Gaa J, Heemann U (2008) Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology (Oxf) 47:1535–1538

    CAS  Article  Google Scholar 

  43. Scheel PJ Jr., Feeley N, Sozio SM (2011) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 154:31–36

    Article  PubMed  Google Scholar 

  44. Binder M, Uhl M, Wiech T et al (2012) Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 71:311–312

    CAS  Article  PubMed  Google Scholar 

  45. Alberici F, Palmisano A, Urban ML et al (2013) Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 72:1584–1586

    CAS  Article  PubMed  Google Scholar 

  46. Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol 23:339–353

    Article  PubMed  Google Scholar 

  47. Palmisano A, Maritati F, Vaglio A (2018) Chronic Periaortitis: an update. Curr Rheumatol Rep 20:80

    Article  CAS  PubMed  Google Scholar 

  48. Carruthers MN, Topazian MD, Khosroshahi A et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74:1171–1177

    CAS  Article  PubMed  Google Scholar 

  49. Khosroshahi A, Wallace ZS, Crowe JL et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67:1688–1699

    CAS  Article  PubMed  Google Scholar 

  50. Floros N, Papadakis M, Wagenhauser MU et al (2017) Outcomes after open surgery for inflammatory abdominal aortic aneurysm: a 10-year single-center experience. Ann Vasc Surg 43:144–150

    Article  PubMed  Google Scholar 

  51. Stone WM, Fankhauser GT, Bower TC et al (2012) Comparison of open and endovascular repair of inflammatory aortic aneurysms. J Vasc Surg 56:951–955 (discussion 5–6)

    Article  PubMed  Google Scholar 

  52. Kakkos SK, Papazoglou KO, Tsolakis IA, Lampropoulos G, Papadoulas SI, Antoniadis PN (2015) Open versus endovascular repair of inflammatory abdominal aortic aneurysms: a comparative study and meta-analysis of the literature. Vasc Endovascular Surg 49:110–118

    Article  PubMed  Google Scholar 

  53. Dietz SM, van Stijn D, Burgner D et al (2017) Dissecting Kawasaki disease: a state-of-the-art review. Eur J Pediatr 176:995–1009

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  54. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatr Electron Pages 96:1057–1061

    CAS  Google Scholar 

  55. McCrindle BW, Rowley AH, Newburger JW et al (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135:e927–e999

    Article  PubMed  Google Scholar 

  56. Terai M, Shulman ST (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 131:888–893

    CAS  Article  PubMed  Google Scholar 

  57. Leib ES, Restivo C, Paulus HE (1979) Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 67:941–947

    CAS  Article  PubMed  Google Scholar 

  58. Pagnoux C, Seror R, Henegar C et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616–626

    Article  PubMed  Google Scholar 

  59. Ribi C, Cohen P, Pagnoux C et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62:1186–1197

    Article  PubMed  Google Scholar 

  60. Samson M, Puechal X, Devilliers H et al (2014) Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev 13:197–205

    Article  PubMed  Google Scholar 

  61. Pagnoux C, Quemeneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67:1117–1127

    CAS  Article  PubMed  Google Scholar 

  62. Schirmer JH, Moosig F (2018) Update: polyarteritis nodosa. Z Rheumatol 77:397–408

    Article  PubMed  Google Scholar 

  63. Gayraud M, Guillevin L, le Toumelin P et al (2001) Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675

    CAS  Article  PubMed  Google Scholar 

  64. Guillevin L, Mahr A, Cohen P et al (2004) Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 51:482–487

    CAS  Article  PubMed  Google Scholar 

  65. Hernandez-Rodriguez J, Hoffman GS (2012) Updating single-organ vasculitis. Curr Opin Rheumatol 24:38–45

    Article  PubMed  Google Scholar 

  66. Nanthapisal S, Murphy C, Omoyinmi E et al (2016) Deficiency of Adenosine Deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 68:2314–2322

    CAS  Article  PubMed  Google Scholar 

  67. Rits Y, Oderich GS, Bower TC et al (2010) Interventions for mesenteric vasculitis. J Vasc Surg 51:392–400 (e2)

    Article  PubMed  Google Scholar 

  68. Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594

    CAS  Article  PubMed  Google Scholar 

  69. McGeoch L, Twilt M, Famorca L et al (2016) CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol 43:97–120

    CAS  Article  PubMed  Google Scholar 

  70. Ntatsaki E, Carruthers D, Chakravarty K et al (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxf) 53:2306–2309

    CAS  Article  Google Scholar 

  71. Schirmer JH, Aries PM, de Groot K et al (2017) S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol 76:77–104

    Article  PubMed  Google Scholar 

  72. Hellmich B (2017) Current guidelines on ANCA-associated vasculitides: common features and differences. Z Rheumatol 76:133–142

    CAS  Article  PubMed  Google Scholar 

  73. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U (2016) ANCA-associated vasculitis – clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12:570–579

    CAS  Article  PubMed  Google Scholar 

  74. Thiel J, Troilo A, Salzer U et al (2017) Rituximab as induction therapy in Eosinophilic Granulomatosis with Polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 5:1556–1563

    Article  PubMed  Google Scholar 

  75. Mohammad AJ, Hot A, Arndt F et al (2016) Rituximab for the treatment of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). Ann Rheum Dis 75:396–401

    CAS  Article  PubMed  Google Scholar 

  76. Wechsler ME, Akuthota P, Jayne D et al (2017) Mepolizumab or placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 376:1921–1932

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  77. Gulati K, McAdoo SP (2018) Anti-glomerular basement membrane disease. Rheum Dis Clin North Am 44:651–673

    Article  PubMed  Google Scholar 

  78. Apaydin S (2018) The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis. Transfus Apher Sci 57:8–12

    Article  PubMed  Google Scholar 

  79. Huart A, Josse AG, Chauveau D et al (2016) Outcomes of patients with Goodpasture syndrome: a nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun 73:24–29

    Article  PubMed  Google Scholar 

  80. McAdoo SP, Tanna A, Hruskova Z et al (2017) Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92:693–702

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  81. De Vita S, Quartuccio L, Isola M et al (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64:843–853

    Article  CAS  PubMed  Google Scholar 

  82. Sneller MC, Hu Z, Langford CA (2012) A randomized controlled trial of rituximab following failure of antiviral therapy for Hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64:835–842

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  83. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D (2015) Cryoglobulinemia vasculitis. Am J Med 128:950–955

    Article  PubMed  Google Scholar 

  84. Blank N, Lorenz HM (2016) Cryoglobulinemic vasculitis. Z Rheumatol 75:303–315

    CAS  Article  PubMed  Google Scholar 

  85. Ramos-Casals M, Robles A, Brito-Zeron P et al (2006) Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 36:189–196

    Article  PubMed  Google Scholar 

  86. Lo Gullo R, De Filippis L, Caliri A, Bagnato G (2005) Successful treatment of necrotizing vasculitic lesions after infusion of iloprost in a patient with cryoglobulinemia and chronic HCV infection. Clin Exp Rheumatol 23:912–913

    CAS  PubMed  Google Scholar 

  87. Audemard-Verger A, Terrier B, Dechartres A et al (2017) Characteristics and management of IgA Vasculitis (Henoch-Schonlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol 69:1862–1870

    CAS  Article  PubMed  Google Scholar 

  88. Lafayette RA, Canetta PA, Rovin BH et al (2017) A randomized, controlled trial of Rituximab in IgA Nephropathy with Proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313

    CAS  Article  PubMed  Google Scholar 

  89. Rauen T, Fitzner C, Eitner F et al (2018) Effects of two immunosuppressive treatment protocols for IgA Nephropathy. J Am Soc Nephrol 29:317–325

    CAS  Article  PubMed  Google Scholar 

  90. Winthrop KL, Baddley JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 77:631–633

    CAS  Article  PubMed  Google Scholar 

  91. Hellmich B, Flossmann O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibodyassociatedvasculitis. Ann Rheum Dis 66:605–617

    CAS  Article  PubMed  Google Scholar 

  92. De Virgilio A, Greco A, Maqliulo G et al (2016) Polyarteriitis nodosa: a contemporary overview. Autoimmun Rev 15:564–570

    Article  PubMed  Google Scholar 

  93. Audemard-Verger A, Pillebout E, Guillevin L (2015) IgA vasculitis (Henoch-Shönlein purpura) in adults: Diagnostic and therapeutic aspects. Autoimmun Rev 14:579–585

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. O. Becker.

Ethics declarations

Interessenkonflikt

M. O. Becker, B. Maurer und O. Distler geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Becker, M.O., Maurer, B. & Distler, O. Therapiestrategien bei systemischen Vaskulitiden. Gefässchirurgie 24, 152–161 (2019). https://doi.org/10.1007/s00772-019-0506-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00772-019-0506-0

Schlüsselwörter

  • Systemische Vaskulitis
  • Behandlung
  • Arteriitis
  • ANCA-assoziierte Vaskulitis
  • Biologika

Keywords

  • Systemic vasculitis
  • Treatment
  • Arteritis
  • ANCA-associated vasculitis
  • Biologicals